ElendiLabs Logo
Back to Articles

Need Regulatory Help? Try Our Platform

Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.

Registration

December 16, 2024

Approximately 5 minutes

Navigating Medical Device Registration in Indonesia: MoH Approval, CSDT, and Local Agents

Medical Device Registration and Approval in Indonesia

Medical devices and In Vitro Diagnostic (IVD) products must secure a registration number and a product license (known as the Distribution Approval Number, or NIE - Nomor Izin Edar) from the Ministry of Health (MoH) before they can be legally imported and sold in Indonesia. The MoH serves as the sole governing authority, overseeing pre-market evaluation, post-market surveillance, and standardization.


Key Requirements for Foreign Manufacturers

The Indonesian regulatory structure places crucial responsibility on a local entity:

  • License Holder Requirement: Foreign manufacturers cannot hold the license directly. Registration must be submitted by a local entity, which must be a local, licensed distributor or a Sole Importer (Local Agent). This entity holds the NIE on behalf of the foreign manufacturer.
  • Non-Transferability: The product license is non-transferable, and only one license can be valid per device at any given time. Transferring a license requires canceling the original and submitting a new application, a process that mandates the cooperation of the original license holder.
  • Reference Country Approval: While Home Country approval is not required, foreign manufacturers must provide evidence of approval from a designated Reference Country (Australia, Canada, European Union, Japan, or the United States).
  • Quality System Certification: Registration mandates a valid ISO 13485 certificate to certify the quality system of the manufacturing facilities.

Classification and Review Timeline

Indonesia's medical device classification system follows the Global Harmonization Task Force (GHTF) guidelines and the ASEAN Medical Devices Directive (AMDD), dividing devices into four risk categories. The review time is relatively quick compared to other markets in the region:

Risk ClassDescriptionReview Timeline (Approx.)Government Fee (Approx.)
Class ALow risk15 daysUS$115 (IDR 1,500,000)
Class BLow to moderate risk30 daysUS$230 (IDR 3,000,000)
Class CModerate to high risk30 daysUS$230 (IDR 3,000,000)
Class DHigh risk45 daysUS$340 (IDR 5,000,000)

Documentation and Compliance

Applications are submitted through the MoH's online registration system (Kemenkes platform) using documentation largely based on the ASEAN Common Submission Dossier Template (CSDT). Required documents typically include:

  1. Executive Summary.
  2. Device Labeling and Instructions for Use (IFU). (Note: Some documents, especially IFU and labeling for home-use products, must be translated into Indonesian (Bahasa)).
  3. Risk Analysis Report and Clinical Evaluation Report (CER).
  4. ISO 13485 Certificate.
  5. Declaration of Conformity and Free Sales Certificate.
  6. Manufacturer's Letter of Authorization to the local agent.

Product licenses are valid for two to five years, depending on the validity of the Letter of Authorization, and can be renewed through an administrative process.

Ask Anything

We'll follow up with you personally.

100% response rate • Reply within 7 business days

Your email will not be published. We'll only use it to notify you when we respond.

Questions & Answers (5)

A
Guest

Our Software as a Medical Device (SaMD) uses a cloud-based server hosted on AWS Singapore. With Indonesia's PDP Law (Personal Data Protection) coming into full enforcement in 2026, does the MoH require our clinical data servers to be physically located in Indonesia? Furthermore, what specific 'Cybersecurity Maturity Level' certificate must we provide during the technical evaluation of the CSDT?

ElendiLabs

Data Residency: For "Strategic Public Data" , the data must reside on servers located within Indonesia. For private health data, while cross-border transfer is permitted, you must appoint a Data Protection Officer (DPO) in Indonesia and conduct a Data Protection Impact Assessment (DPIA). • Cybersecurity Evaluation: During the Regalkes technical review, you are now required to submit a Vulnerability Assessment and Penetration Testing (VAPT) report. The MoH's cybersecurity team will specifically check for compliance with ISO/IEC 27001 or the local BSSN (National Cyber and Crypto Agency) standards for any device with internet connectivity

A
Guest

Under the Permenkes 11/2025 framework, Indonesia has introduced real-time adverse event reporting for Class C and D devices. If an incident occurs in a third country (e.g., Japan or Germany), do we need to report it to the Indonesian MoH within 48 hours, even if no such incident has occurred locally in Jakarta? How does this synchronize with the global Field Safety Corrective Action (FSCA) notifications in the Regalkes portal?

ElendiLabs

Global-to-Local Reporting: Yes, Indonesia now mandates that any Serious Adverse Event (SAE) or FSCA initiated globally must be reported to the MoH within 5 working days of the global notification. If the incident involves a fatality or severe injury, the window narrows to 48 hours. • System Integration: You must ensure your local NIE holder is active on the Vigilance E-Reporting module. Failure to report global recalls that affect the same model registered in Indonesia might lead to immediate blacklisting of the manufacturer's brand across all current and future NIE applications.

A
Guest

我们目前在印尼有一个独家经销商持有我们的 NIE。如果我们在 2026 年决定更换合作伙伴,但原经销商拒绝签署‘释放函 (Letter of Release)’。文章中提到的‘6个月自动撤销’机制在 Regalkes 系统中是如何操作的?在此期间我们的货物是否可以继续进口?

ElendiLabs

强制条款: 2026 年系统已集成该功能。如果制造商通过 Letter of Termination 证明合作终止,且原经销商不配合,制造商可以向卫生部申诉。 • 冷却期限制: 在这 6 个月的“行政处理期”内,原有的 NIE 通常有机会被挂起 (Suspended),这意味着无法进行新的进口清关。 • 最佳方案: 为了避免长达半年的断供,建议在 2026 年初始注册时,利用 第三方机构作为 Independent License Holder,而非直接让经销商持有证书。

A
Guest

我们计划将一款 C 类高端影像设备引入印尼公立医院市场。根据最新的采购政策,如果同类产品的本土化比例 (TKDN) 已经超过 40%,外资全进口设备是否会被彻底从 E-Katalog 中‘冻结’?如果我们在巴淡岛仅进行后期组装,是否足以获得 25% 以上的 TKDN 以维持采购资格?

ElendiLabs

冻结机制: 2026 年印尼执行更严格的“进口替代”政策。若某类器械已有 3 家以上本地制造商且 TKDN 均 > 40%,政府招标将优先甚至只允许购买本土产品。 • 组装策略: 仅后期组装(SKD/CKD)在 2026 年的算法中可能难以达到 25%。现在的 TKDN 计算不仅看人工成本,更看重研发投入和原材料本地采购比例。建议您进行“TKDN 预审计”,若无法达标,应考虑与持有 IDAK 的本地合作伙伴建立深度的技术转让合作。

A
Guest

我们有一款 A 类低风险外科耗材,根据 42/2024 号政府条例,截止日期是 2026 年 10 月 17 日。如果我们的产品不含任何动物源成分(纯合成材料),我们是否仍需通过 BPJPH(清真产品保障机构)获得认证?对于尚未到期的 B/C 类产品,如果现在注册 NIE(营销许可),标签上是否必须提前标注清真或非清真状态?

ElendiLabs

强制性要求: 是的,所有进入印尼的 A 类器械必须在 2026 年 10 月 17 日前完成清真认证或登记。即使不含动物成分,也需获得“清真证书”以证明生产链未受污染。 • 非清真标注: 如果产品含有非清真成分(如猪源胶原),您不必通过认证,但必须按照新规在标签上显著标注“非清真 (Non-Halal)”。 • 预见性标签: 对于 B/C 类器械(强制期限较晚),目前虽不强制,但卫生署建议在 2026 年新申请 NIE 时,在 ASEAN CSDT 文档中明确声明其成分状态,以避免未来在 2029/2034 年截止日前再次进行昂贵的标签变更。

Need Expert Guidance?

Contact us at contact@elendilabs.com / +852 4416 5550